Kerendia

Finerenone, the active ingredient in Kerendia, is a mineralocorticoid receptor antagonist presented as a 10 mg/20 mg oral tablet for oral use. It treats chronic kidney disease in adults with type 2 diabetes.

GNH USA supplies Kerendia as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kerendia is a mineralocorticoid receptor antagonist indicated for chronic kidney disease associated with type 2 diabetes. - Chronic kidney disease with type 2 diabetes: slows decline of renal function and reduces albuminuria. - Cardiovascular risk in this population: lowers incidence of cardiovascular events. - Renal fibrosis progression: mitigates inflammatory and fibrotic pathways in kidney tissue.

Finerenone may cause several adverse reactions.

Common Side Effects: - Hyperkalemia: elevated serum potassium levels. - Dizziness or light‑headedness. - Nausea or gastrointestinal discomfort. - Headache.

Serious or Rare Side Effects: - Severe hyperkalemia leading to cardiac arrhythmia. - Acute kidney injury or worsening renal function. - Marked hypotension. - Hepatic injury. - Allergic reactions such as rash or angioedema.

Finerenone requires careful monitoring and patient selection. - Monitor serum potassium: check levels regularly, especially when combined with potassium‑sparing agents. - Monitor renal function: assess eGFR before initiation and periodically thereafter. - Caution with ACE inhibitors or ARBs: increased risk of hyperkalemia. - Contraindicated in pregnancy: safety not established; avoid unless benefit outweighs risk. - Store below 25°C: keep in the original packaging, protect from moisture.

Finerenone can interact with several medicines that affect potassium balance or renal function.

Major Interactions (Avoid): - Potassium‑sparing diuretics (e.g., spironolactone, amiloride): additive hyperkalemia risk. - ACE inhibitors or ARBs: heightened hyperkalemia potential. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may impair renal function.

Moderate Interactions (Monitor Closely): - Digoxin: altered serum concentrations may occur. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase finerenone exposure.